How Dangerous Is Xolair?

David Fuller

Last Updated On: September 25, 2025

When starting a new treatment, one of the first concerns is safety. With Xolair (omalizumab), a biologic medication used to treat allergic asthma, chronic hives, nasal polyps, and now food allergies, this concern is especially relevant. Many patients gain meaningful relief, but Xolair also carries certain risks that should be carefully considered.

The EXCELS study, which followed over 5,000 patients, found higher rates of heart and circulation-related events compared to untreated asthma patients. Because Xolair is often prescribed for more severe disease, some of this difference may reflect underlying illness rather than the drug itself.

Xolair also carries an FDA boxed warning for anaphylaxis, a rare but serious allergic reaction that can occur even after months of therapy. In this article, we’ll review the evidence, discuss possible side effects, and weigh the risks against Xolair’s proven benefits.

Key Takeaways

• Xolair (omalizumab) is approved for the treatment of severe asthma, chronic urticaria (hives), nasal polyps, and food allergies.
• The most serious risk is anaphylaxis, which can occur unpredictably and is highlighted in the FDA black box warning.
• Some studies suggest higher rates of cardiovascular and cerebrovascular events, but asthma severity may contribute to this finding.
• Cancer signals have been observed in early research, though no causal link has been proven.
• Xolair may increase rthe isk for infections, particularly parasitic ones, though serious infections are uncommon.
• Careful patient selection, monitoring, and emergency readiness help reduce risks while allowing patients to benefit from treatment.

About: Operating since 2016, Med Supply Solutions is known for being one of the industry’s top and trusted suppliers of cosmetic and viscosupplementation products. If you’re looking to buy Xolair online, contact our sales department for more information.

Anaphylaxis Risk with Xolair and Required Safety Precautions

One of the most important safety concerns with Xolair (omalizumab) is the risk of anaphylaxis, a severe allergic reaction. This risk is highlighted in the drug’s FDA black box warning because reactions can occur unpredictably—even after months of treatment. While rare, knowing the facts helps patients and providers stay alert and prepared.

Some key facts about Xolair anaphylaxis risk include:

• Around 0.1% of patients (3 in ~3,500) developed anaphylaxis in clinical studies.
  
• Real-world monitoring suggests the risk may be closer to 0.2%, underscoring the need for vigilance.
  
• Most reactions occur within the first three doses, but cases have been reported even after a year of treatment.
  
• Symptoms may include sudden swelling, difficulty breathing, hives, or dizziness, which can become life-threatening without immediate care.

Recommended Safety Precautions

• Xolair should be given in settings equipped to handle emergencies.
  
• Patients are usually monitored for at least one hour after the first few injections.
  
• Providers should explain early warning signs clearly so patients know when to seek urgent help.
  
• Some clinicians recommend carrying an epinephrine auto-injector in case of delayed reaction.

Although rare, the unpredictable nature of anaphylaxis makes it one of the most serious risks associated with Xolair. With proper monitoring and education, patients can still benefit safely from treatment.

Cardiovascular, Cerebrovascular, and Other Safety Concerns Linked to Xolair

Beyond anaphylaxis, questions have been raised about Xolair’s impact on cardiovascular and cerebrovascular health. In the EXCELS study, patients on Xolair had slightly higher rates of events like heart attacks, transient ischemic attacks (TIAs), and pulmonary hypertension compared to those with asthma not on the drug. However, many of these patients also had more severe baseline asthma, which could partly explain the difference.

A review of 25 randomized trials found no clear link between Xolair and cardiovascular events, though those trials involved younger patients and shorter follow-up. Other reported side effects include sinus infections, joint pain, and injection-site reactions.

For patients with existing heart or vascular disease, they may need closer monitoring, particularly if they use Xolair for the treatment of chronic asthma or food allergies.

Post-Marketing Warnings, Malignancy Signals, and Infection Risks with Xolair

Post-marketing surveillance and long-term studies have provided additional insights into Xolair safety:

• Malignancy Signals: Some early studies showed a slightly higher rate of malignancies (0.5% in Xolair users vs. 0.2% in controls). Later clinical trials and observational studies have not confirmed a direct link.
  
• Infection Risk: Because Xolair reduces IgE activity, which plays a role in fighting parasites, there is a theoretical risk of geohelminth (parasitic worm) infections. Some studies have also noted higher rates of sinus and respiratory infections, but serious infections are rare.
  
• Long-term Monitoring: The EXCELS study continues to track outcomes. While some signals for cardiovascular or malignancy risk remain under investigation, there isn’t any established definitive long-term hazard.

This ongoing monitoring reflects a cautious approach: keeping patients informed while continuing to clarify Xolair’s long-term safety.

Balancing Xolair Risks and Benefits in Clinical Practice

Despite its risks, Xolair has transformed care for many patients with severe asthma, chronic hives, nasal polyps, and food allergies. The key is careful patient selection and monitoring. Below are some clinical considerations:

• Screening: Avoid prescribing Xolair to patients with a history of severe hypersensitivity to omalizumab. Consider coexisting cardiovascular disease or infection risk.
  
• Treatment Setting: Start treatment in a clinic prepared for emergencies. Self-administration may be an option later once the healthcare professional establishes treatment safety with the patient.
  
• Therapeutic Benefit: It can reduce asthma flare-ups, improve control of chronic urticaria, and help lower the risk of reactions in patients who want to use Xolair for a food allergy. Many report significant improvements in quality of life.
  
• Follow-up: Monitor for cardiovascular status, infection signs, allergic reactions, and—when appropriate—potential malignancy concerns.

By weighing risks against benefits and engaging in open dialogue, providers and patients can make confident, informed choices about treatment.

Conclusion

So, how dangerous is Xolair? The answer depends on the individual patient, their health history, and how closely they are monitored. The most serious and immediate concern is anaphylaxis, which is why Xolair carries an FDA black box warning. Other potential risks—cardiovascular events, malignancy signals, and infections—remain under investigation, with no clear causal link confirmed.

For many patients, the benefits of Xolair, from reducing asthma exacerbations to improving chronic hives and managing food allergies, outweigh the risks when it is prescribed thoughtfully and monitored carefully. Ongoing vigilance, patient education, and shared decision-making remain central to safe use.

FAQs

1. What is the Xolair black box warning?

The black box warning highlights the risk of severe allergic reactions (anaphylaxis). Healthcare professionals should initiate treatment in a medical setting equipped for emergencies, particularly during the first doses.

2. How dangerous is Xolair for long-term use with respect to cancer?

Some early studies reported slightly higher cancer rates in Xolair users, but larger trials and long-term observational studies have not proven a direct connection. For high-risk patients, they require continued monitoring.

3. Does Xolair significantly increase infection risk?

There may be a higher risk of certain infections, especially parasitic (geohelminth) infections, since IgE plays a role in immune defense. More common side effects include sinus and respiratory infections. However, serious systemic infections are rare.

4. Is Xolair safe for patients with cardiovascular disease or risk factors?

Patients with existing heart or vascular disease should be monitored carefully. Some studies observed higher rates of events like heart attacks or TIAs, though part of this may reflect the severity of asthma in treated patients rather than the drug itself.

References

Iribarren C, Rahmaoui A, Long AA, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma. Journal of Allergy and Clinical Immunology. 2016;139(5):1489-1495.e5. doi:10.1016/j.jaci.2016.07.038

Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clinical & Experimental Allergy. 2009;39(6):788-797. doi:10.1111/j.1365-2222.2009.03214.x

FDA Drug Safety Communication: FDA approves label changes for asthma drug Xolair (omalizumab), including describing slightly higher risk of heart and brain adverse events. U.S. Food And Drug Administration. Updated February 26, 2018. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-asthma-drug-xolair-omalizumab-including